Predict your next investment

Ybrain company logo
HEALTHCARE | Medical Devices & Equipment / Therapeutic Devices
ybrain.com

See what CB Insights has to offer

Founded Year

2013

Stage

Series C | Alive

Total Raised

$15.02M

Last Raised

$5.32M | 2 yrs ago

About Ybrain

Ybrain is a brain science healthcare company that commercializes home-based neuropsychiatry diagnosis, treatment, and management solutions for people with mental illnesses. The company's products include MINDD STIM, a medical-grade noninvasive brain stimulation system that uses weak current to stimulate the human brain and help patients suffering from mental health conditions such as depression; and MINDD SCAN, a wireless EEG system that allows operators to quickly complete preparation and collection of EEG signals.

Ybrain Headquarter Location

#228, 54, Changeop-ro Sujeong-gu, Seongnam-si, Gyeonggi-do

Republic of Korea, 13449,

South Korea

Latest Ybrain News

YBrain’s electroceutical targeting depression OKed for commercial use

Apr 28, 2021

닫기 YBrain said on Wednesday that it has received local approval for an electroceutical head wearable to treat depression. An electroceutical, combined from electronic and pharmaceutical, refers to a device that stimulates brain nerves. The Ministry of Food and Drug Safety granted the first-in-class indication for YBrain’s electroceutical to improve major depressive disorders and symptoms. The electroceutical prescription prevents drug misuse/abuse and allows treatment at home. YBrain said it completed the phase-3 clinical trial of the electroceutical as monotherapy for at-home treatment in September, which the company said was the first time in the world. The study evaluated the efficacy and safety of transcranial direct current stimulation (tDCS) in 65 patients with mild to moderate depressive disorder to improve depressive symptoms. The results showed that 57.4 percent of the participants, and 62.8 percent of those who complied with the protocol, recovered their depressive symptoms to the normal level. 2020 tDCS guidelines, published by an international journal under Collegium Internationale Neuro-Psychopharmacologicum (CINP), stated that evidence for the therapeutic effect of YBrain’s electroceutical was Level A, or effective. YBrain expects that its tCDS device will pass the regulator’s review on new medical technology as monotherapy for depression treatment. The company said it would apply for the U.S. FDA’s De Novo process. The FDA uses the process to review approval for new medical devices that assure safety and effectiveness. “We are the first in the world to commercialize an electroceutical platform as a monotherapy that can be applied to hundreds of patients simultaneously for treating depression,” an official at YBrain said. As a non-medication treatment, the electroceutical can provide a new treatment option to patients who are struggling to treat depression due to the limited efficacy and various side effects of existing antidepressants, he went on to say. Especially when Korea ranks first in the suicide rate among OECD members, the new device will help solve medical and social problems. Koreans hesitate to visit a mental health institution to treat depression, he added. The Korean NeuroPsychiatric Association covered tCDS as a major topic in its spring conference on April 8. KNPA’s 2021 Korean-type depressive disorder treatment guidelines mentioned tCDS as a complementary and new treatment technique.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Ybrain

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Ybrain in 1 CB Insights research brief, most recently on May 24, 2021.

Expert Collections containing Ybrain

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ybrain is included in 6 Expert Collections, including Digital Therapeutics.

D

Digital Therapeutics

341 items

Companies developing and enabling evidence-based, software-driven therapeutic interventions to prevent, manage, or treat a medical disorder or disease. (*Scope follows the Digital Therapeutics Alliance definition)

M

Mental Health/Wellness Tech

902 items

This collection includes companies applying technology to problems of emotional, psychological, and social well-being. Examples include companies working in areas such as substance abuse, eating disorders, stress reduction, depression, PTSD, and anxiety.

W

Wearable Computing

377 items

Wearable computing is broadly defined as companies developing devices worn or placed on the body that are equipped with technology, which can range from wearable medical devices to AR/VR headsets to GPS pet collars.

C

Consumer Hardware

2,912 items

C

CES 2018 Exhibitors

760 items

Companies that will be exhibiting at CES 2018

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

Ybrain Patents

Ybrain has filed 22 patents.

The 3 most popular patent topics include:

  • Neurophysiology
  • Neurotechnology
  • Electrotherapy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/31/2019

9/7/2021

Electrotherapy, Neurotechnology, Neurophysiology, Psychiatric diagnosis, Neurological disorders

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

5/31/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/7/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Electrotherapy, Neurotechnology, Neurophysiology, Psychiatric diagnosis, Neurological disorders

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Ybrain Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ybrain Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.